Reviews
2 Results
- Review Article
The use of molecular assays in the management of viral hepatitis
Digestive and Liver DiseaseVol. 40Issue 6p395–404Published online: March 4, 2008- A. Mangia
- F. Antonucci
- M. Brunetto
- M. Capobianchi
- S. Fagiuoli
- M. Guido
- and others
Cited in Scopus: 17Molecular assays are instrumental in the clinical management of viral hepatitis. During the past years, a wide variety of molecular assays have been developed and implemented. This considerably improved the understanding of the natural history and pathogenesis of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Hepatitis delta virus (HDV) hepatitis, but also caused uncertainties in the selection of the most appropriate assays for clinical requirements. Indeed, a rational choice and application of these assays requires adequate knowledge of the performance of the single test. - Review Article
Prophylaxis and treatment of hepatitis B in immunocompromised patients
Digestive and Liver DiseaseVol. 39Issue 5p397–408Published in issue: May, 2007- A. Marzano
- E. Angelucci
- P. Andreone
- M. Brunetto
- R. Bruno
- P. Burra
- and others
Cited in Scopus: 200The literature on hepatitis B virus (HBV) in immunocompromised patients is heterogeneous and referred mainly to the pre-antivirals era. Today a rational approach to the problem of hepatitis B in these patients provides for: (a) the evaluation of HBV markers and of liver condition in all subjects starting immunosuppressive therapies (baseline), (b) the treatment with antivirals (therapy) of active carriers, (c) the pre-emptive use of antivirals (prophylaxis) in inactive carriers, especially if they are undergoing immunosuppressive therapies judged to be at high risk, (d) the biochemical and hepatitis B surface antigen (HBsAg) monitoring (or universal prophylaxis, in case of high risk immunosuppression) in subjects with markers of previous contact with HBV (HBsAg negative and anti-HBc positive), in order to prevent reverse seroconversion.
